Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
32498
CAS Number:
91421-42-0
Rubitecan
Purity:
≥ 96 % (HPLC)
Synonym(s):
9-Nitrocamptothécine, Orathécine
Documents
$127.79 /25 mg
Taille
Request Bulk Quote
Product Information

Conserver le récipient bien fermé dans un endroit sec et bien aéré.

Synonyms
9-Nitrocamptothécine, Orathécine
CAS Number
91421-42-0
Purity
≥ 96 % (HPLC)
Molecular Formula
C20H15N3O6
Molecular Weight
393.35
MDL Number
MFCD06656294
PubChem ID
15200290
Melting Point
268 ?C
Appearance
Poudre blanc cassé à jaune
Conditions
Magasin chez RT
General Information
Synonyms
9-Nitrocamptothécine, Orathécine
CAS Number
91421-42-0
Purity
≥ 96 % (HPLC)
Molecular Formula
C20H15N3O6
Molecular Weight
393.35
MDL Number
MFCD06656294
PubChem ID
15200290
Melting Point
268 ?C
Appearance
Poudre blanc cassé à jaune
Conditions
Magasin chez RT
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
Non
Antibiotic
Non
DEA-regulated
Non
Warnings
-
Applications

Rubitecan is widely utilized in research focused on:

  • Cancer Treatment: This compound is primarily explored for its potential as an anti-cancer agent, particularly in treating various solid tumors. Its unique structure allows it to interfere with cancer cell proliferation.
  • Pharmaceutical Development: Rubitecan serves as a lead compound in the development of new chemotherapeutic drugs, offering insights into drug design and efficacy in targeting cancer cells.
  • Drug Formulation: In the pharmaceutical industry, it is used in formulating targeted drug delivery systems, enhancing the bioavailability and therapeutic effects of cancer treatments.
  • Research in Drug Resistance: Researchers study Rubitecan to understand mechanisms of drug resistance in cancer therapies, helping to develop strategies to overcome this challenge.
  • Combination Therapies: It is being investigated for use in combination with other chemotherapeutic agents to improve treatment outcomes and reduce side effects in cancer patients.

Citations